When Should Surgical Cytoreduction in Advanced Ovarian Cancer Take Place?
Open Access
- 25 October 2009
- journal article
- review article
- Published by Hindawi Limited in Journal of Oncology
- Vol. 2010, 1-6
Abstract
Initial surgical management is commonly accepted to date as paramount in the treatment of women presenting with epithelial ovarian cancer and permits the assessment of the disease (staging), the histological confirmation of disease type and grade, and the practice of maximal debulking preceding platinum-based chemotherapy. Many studies have shown that the volume of residual disease after initial surgical cytoreduction inversely correlates with survival. Thus, women with optimal debulking performed by a trained specialist have improved median survival. In this review, we will focus on the answers gleaned from clinical trials on primary and interval surgery, which prompts the question on the timing of surgery in respect to chemotherapy. Interval debulking surgery (IDS) is secondary cytoreduction following primary debulking and is carried out in between the courses of chemotherapy. The major clinical trials and the latest systematic reviews seem unable to give any definitive guidance or recommendation for clinical practice. The choice of aggressive primary cytoreduction or upfront chemotherapy followed by second line surgical cytoreduction seems among others to have to be individualized according to tumour load, prediction of its resectability, and response to chemotherapy. The role of tumour biology must also be kept in mind. Finally, concrete answers are awaited on the timing of surgery from the ongoing prospective randomized control trials (CHORUS and EORTC 55971) though preliminary data from the latter have already been presented at major meetings (IGCS 2008; SGO 2009) and ignited strong debate.Keywords
This publication has 35 references indexed in Scilit:
- Interval debulking surgery for advanced epithelial ovarian cancer2009
- Aggressive surgical strategies in advanced ovarian cancer: A monocentric study of 203 stage IIIC and IV patientsEuropean Journal of Surgical Oncology, 2009
- The role of secondary cytoreduction in the management of the first relapse in epithelial ovarian cancerAnnals of Oncology, 2008
- Timing of debulking surgery in advanced ovarian cancerInternational Journal of Gynecological Cancer, 2008
- Treatment of FIGO stage IV ovarian carcinoma: results of primary surgery or interval surgery after neoadjuvant chemotherapy: a retrospective studyInternational Journal of Gynecological Cancer, 2007
- CA125 levels are a weak predictor of optimal cytoreductive surgery in patients with advanced epithelial ovarian cancerInternational Journal of Gynecological Cancer, 2003
- Procedures Required to Accomplish Complete Cytoreduction of Ovarian Cancer: Is There a Correlation with “Biological Aggressiveness” and Survival?Gynecologic Oncology, 2001
- Epithelial Ovarian Carcinoma: Principles of Primary SurgeryGynecologic Oncology, 1994
- Intervention debulking surgery in advanced epithelial ovarian cancerBJOG: An International Journal of Obstetrics & Gynaecology, 1994
- Secondary cytoreductive surgery in epithelial ovarian cancer: Nonresponders to first-line therapyGynecologic Oncology, 1989